Image
Photo: Getty Images
Breadcrumb

New blood test to better measure advanced Alzheimer's disease

Published

Researchers have demonstrated the first scalable blood test that measures a protein fragment that tracks the buildup of tau tangles — a key sign of Alzheimer's disease.

Researchers at Banner Health, University of Gothenburg, Lund University and other renowned international collaborators have demonstrated the first scalable blood test that measures a protein fragment called eMTBR-tau that tracks the buildup of tau tangles.

Because it can be measured in blood, the blood test could offer a much less invasive option compared to spinal fluid draws or specialized brain scans, particularly in clinical settings where tau-PET is unavailable. In Alzheimer's disease, a protein called tau becomes abnormal and clumps into tangles inside brain cells. These tangles spread through the brain over time and are closely linked to cognitive decline and symptom severity.

In a study published in JAMA, the newly developed blood test accurately detected advanced tau pathology and showed clearer differences between early and late-stage disease compared with p-tau217, the blood marker most widely used in Alzheimer's research and clinical care today. While p-tau217 rises early in the disease process — tracking the buildup of amyloid plaques — it gives limited information about tau tangle buildup in later stages. The new test targets a different biological signal, one that more directly tracks how tau tangles spread through the brain, suggesting the two markers may work together to give a fuller picture of how the disease progresses. 

Represents a major step forward 

Until now, measuring this marker required specialized equipment found in only a few labs worldwide. The new test requires a minimal blood sample and can be performed at scale, marking a significant step toward making the test far more widly available for researchers and clinicians to use the test in clinical trials, biological staging of the disease, and eventually routine clinical care.

“Having a simple yet highly scalable way to determine the extent of tau tangle buildup in the brain represents a major step forward in our understanding of Alzheimer’s,” says the study’s senior author Nicholas Ashton, researcher at the University of Gothenburg and senior director of Banner’s Fluid Biomarker Program at Banner Sun Health Research Institute. “While p-tau217 detects early signs of Alzheimer's disease, eMTBR-tau measures how far tau tangles have spread. Together, they could help doctors make better treatment decisions and identify the right patients for clinical trials.”

Nicholas Ashton, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, and Banner Sun Health Research Institute, and Niklas Mattson-Carlgren, Lunds University and Skåne University Hospital.
Photo: Göteborgs universitet / Tove Smeds, Lunds universitet

Shared senior author is Professor Niklas Mattsson-Carlgren at Lund University, who is also a specialized neurologist at the Memory Clinic of Skåne University Hospital:

“One of the most challenging tasks in Alzheimer’s disease diagnosis is to establish in a patient with cognitive impairment that Alzheimer’s pathology is not just present, but that is present in a sufficiently advanced biological stage to be a likely explanation for symptoms,” he says. “As a physician managing patients, I am excited about the potential for a blood test to identify and quantify tau pathology in my patients in the future, because this is exactly what is lacking to determine in an accessible way if a patient’s symptoms are likely to be caused by Alzheimer’s pathology.”  

Closely matched advanced methods

The study evaluated 728 participants, including 521 brain donors from two U.S. research programs: Banner's Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program in Sun City, Arizona and University of California, Irvine Alzheimer Disease Research Center, and 207 participants from two imaging cohorts: Lund University (BioFINDER-2) and McGill University in Montreal, Canada (TRIAD cohort). The immunoassay was developed in collaboration with Alamar Biosciences.

In the study, the new blood test results closely matched those from established and advanced methods, confirming its accuracy. Both methods detected advanced tau pathology with similarly high accuracy. Additionally, analysis of brain tissue after death demonstrated that eMTBR-tau was a stronger indicator of overall tau tangle buildup than existing markers.

This blood test is not yet available for clinical use and is not meant to diagnose Alzheimer's disease on its own.

Study: A Plasma eMTBR-Tau Immunoassay for Detection of Advanced Insoluble Tau Pathology